Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 02, 2023 at 05:24 pm EDT
Share
Li Kang Biomedical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 175.45 million compared to TWD 201.87 million a year ago. Revenue was TWD 175.45 million compared to TWD 201.87 million a year ago. Net income was TWD 32.8 million compared to TWD 30.43 million a year ago. Basic earnings per share from continuing operations was TWD 1.22 compared to TWD 1.14 a year ago. Diluted earnings per share from continuing operations was TWD 1.22 compared to TWD 1.13 a year ago.
For the six months, sales was TWD 331.29 million compared to TWD 303.21 million a year ago. Revenue was TWD 331.29 million compared to TWD 303.21 million a year ago. Net income was TWD 60.95 million compared to TWD 44.37 million a year ago. Basic earnings per share from continuing operations was TWD 2.27 compared to TWD 1.66 a year ago. Diluted earnings per share from continuing operations was TWD 2.26 compared to TWD 1.65 a year ago.
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
LI KANG BIOMEDICAL CO., LTD. 
